

# Contents

## Executive Summary .....

1

### Introduction.....

- 1.1 Overview of the Industry .....
- 1.2 Overview of the Report .....

2

### Overall Deal Activity of the Top 12 Pharma Companies .....

- 2.1 M&A Deal Activity of the Top 12 Companies .....
- 2.1.1 Leading Companies in M&A Dealmaking .....
- 2.1.2 Company Comparison of M&A Deal Values .....
- 2.2 Licensing Activity of the Top 12 Companies .....
- 2.2.1 Licensing Deals: 5 Year Total and Average Deal Values .....
- 2.2.2 Licensing Deals: 5 Year Total and Average Upfront Payments .....
- 2.2.3 Are Licensing Activities Adequate to Defend the Patent Cliff Challenge? .....
- 2.2.4 How do Licensing Activities Compare Relative to Sales.....
- 2.3 Comparing Licensing Activity by Development Phase of the Top 12 Companies .....
- 2.3.1 Discovery and Preclinical Stage Deals Dominate Deal Activity .....
- 2.3.2 Analysis of Early-, Mid- and Late-Stage Dealmaking of the Top 12 Companies .....
- 2.3.3 Competition for Late Stage Deals Drives Deal Values.....
- 2.4 Comparing Licensing Activity by Therapeutic Area of the Top 12 Companies .....
- 2.4.1 Most Popular Therapy Areas in Dealmaking .....

3

### Pfizer .....

- 3.1 Key Business and Therapy Areas .....
- 3.2 Overview of Dealmaking .....
- 3.3 M&A Activity.....
- 3.3.1 Key M&A Deals .....
- 3.3.2 Other Key M&A Deals.....
- 3.4 Licensing Strategy and Deal Structures .....
- 3.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....
- 3.4.2 Therapy Area Focus by Sales .....
- 3.4.3 Leading Therapy Areas in Dealmaking.....
- 3.4.4 Total and Average Upfront Values of Top Therapy Areas.....
- 3.4.5 Comparison of Short- and Long-Term Deal Investment .....

4

### Sanofi.....

- 4.1 Key Business and Therapy Areas .....
- 4.2 Overview of Dealmaking .....
- 4.3 M&A Activity.....
- 4.3.1 Key M&A Deals .....
- 4.3.2 Other Key M&A Deals.....
- 4.4 Licensing Strategy and Deal Structures .....
- 4.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....
- 4.4.2 Therapy Area Focus by Sales .....
- 4.4.3 Leading Therapy Areas in Dealmaking.....
- 4.4.4 Total and Average Upfront Values of Top Therapy Areas.....
- 4.4.5 Comparison of Short- and Long-Term Deal Investment .....

5  
**Novartis** .....

5.1 Key Business and Therapy Areas .....

5.2 Overview of Dealmaking .....

5.3 M&A Activity .....

5.3.1 Key M&A Deals .....

5.3.2 Other Key M&A Deals.....

5.4 Licensing Strategy and Deal Structures .....

5.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....

5.4.2 Therapy Area Focus by Sales .....

5.4.3 Leading Therapy Areas in Dealmaking.....

5.4.4 Total and Average Upfront Values of Top Therapy Areas.....

5.4.5 Comparison of Short- and Long-Term Deal Investment .....

6  
**GlaxoSmithKline** .....

6.1 Key Business and Therapy Areas .....

6.2 Overview of Dealmaking .....

6.3 M&A Activity .....

6.3.1 Key M&A Deals .....

6.3.2 Other Key M&A Deals.....

6.4 Licensing Strategy and Deal Structures .....

6.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....

6.4.2 Therapy Area Focus by Sales .....

6.4.3 Leading Therapy Areas in Dealmaking.....

6.4.4 Total and Average Upfront Values of Top Therapy Areas.....

6.4.5 Comparison of Short- and Long-Term Deal Investment .....

7  
**Roche** .....

7.1 Key Business and Therapy Areas .....

7.2 Overview of Dealmaking .....

7.3 M&A Activity .....

7.3.1 Key M&A Deals .....

7.3.2 Other Key M&A Deals.....

7.4 Licensing Strategy and Deal Structures .....

7.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....

7.4.2 Therapy Area Focus by Sales .....

7.4.3 Leading Therapy Areas in Dealmaking.....

7.4.4 Total and Average Upfront Values of Top Therapy Areas.....

7.4.5 Comparison of Short- and Long-Term Deal Investment .....

8  
**AstraZeneca**.....

8.1 Key Business and Therapy Areas .....

8.2 Overview of Dealmaking .....

8.3 M&A Activity.....

8.3.1 Key M&A Deals .....

8.3.2 Other Key M&A Deals.....

8.4 Licensing Strategy and Deal Structures .....

8.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....

8.4.2 Therapy Area Focus by Sales .....

8.4.3 Leading Therapy Areas in Dealmaking.....

8.4.4 Total and Average Upfront Values of Top Therapy Areas.....

8.4.5 Comparison of Short- and Long-Term Deal Investment .....

9  
**Merck & Co** .....

9.1 Key Business and Therapy Areas .....

9.2 Overview of Dealmaking .....

9.3 M&A Activity.....

9.3.1 Key M&A Deals .....

9.3.2 Other Key M&A Deals.....

9.4 Licensing Strategy and Deal Structures .....

9.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....

9.4.2 Therapy Area Focus by Sales .....

9.4.3 Leading Therapy Areas in Dealmaking.....

9.4.4 Total and Average Upfront Values of Top Therapy Areas.....

9.4.5 Comparison of Short- and Long-Term Deal Investment .....

10  
**Johnson & Johnson**.....

10.1 Key Business and Therapy Areas .....

10.2 Overview of Dealmaking .....

10.3 M&A Activity.....

10.3.1 Key M&A Deals .....

10.3.2 Other Key M&A Deals.....

10.4 Licensing Strategy and Deal Structures .....

10.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....

10.4.2 Therapy Area Focus by Sales .....

10.4.3 Leading Therapy Areas in Dealmaking .....

10.4.4 Total and Average Upfront Values of Top Therapy Areas.....

10.4.5 Comparison of Short- and Long-Term Deal Investment .....

11

**Eli Lilly**.....

- 11.1 Key Business and Therapy Areas .....
- 11.2 Overview of Dealmaking .....
- 11.3 M&A Activity.....
  - 11.3.1 Key M&A Deals .....
  - 11.3.2 Other Key M&A Deals.....
- 11.4 Licensing Strategy and Deal Structures .....
- 11.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....
- 11.4.2 Therapy Area Focus by Sales .....
- 11.4.3 Leading Therapy Areas in Dealmaking .....
- 11.4.4 Total and Average Upfront Values of Top Therapy Areas.....
- 11.4.5 Comparison of Short- and Long-Term Deal Investment .....

12

**Abbott**.....

- 12.1 Key Business and Therapy Areas .....
- 12.2 Overview of Dealmaking .....
- 12.3 M&A Activity.....
  - 12.3.1 Key M&A Deals .....
  - 12.3.2 Other Key M&A Deals.....
- 12.4 Licensing Strategy and Deal Structures .....
- 12.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....
- 12.4.2 Therapy Area Focus by Sales .....
- 12.4.3 Leading Therapy Areas in Dealmaking .....
- 12.4.4 Total and Average Upfront Values of Top Therapy Areas.....
- 12.4.5 Comparison of Short- and Long-Term Deal Investment .....

13

**Bristol-Myers Squibb** .....

- 13.1 Key Business and Therapy Areas .....
- 13.2 Overview of Dealmaking .....
- 13.3 M&A Activity.....
  - 13.3.1 Key M&A Deals .....
  - 13.3.2 Other Key M&A Deals.....
- 13.4 Licensing Strategy and Deal Structures .....
- 13.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....
- 13.4.2 Therapy Area Focus by Sales .....
- 13.4.3 Leading Therapy Areas in Dealmaking .....
- 13.4.4 Total and Average Upfront Values of Top Therapy Areas.....
- 13.4.5 Comparison of Short- and Long-Term Deal Investment .....

14

**Bayer**

- 14.1 Key Business and Therapy Areas .....
- 14.2 Overview of Dealmaking .....
- 14.3 M&A Activity.....
  - 14.3.1 Key M&A Deals .....
  - 14.3.2 Other Key M&A Deals.....
- 14.4 Licensing Strategy and Deal Structures .....
- 14.4.1 How Does the Company's Dealmaking Compare with its Peer Group.....
- 14.4.2 Therapy Area Focus by Sales .....
- 14.4.3 Leading Therapy Areas in Dealmaking .....
- 14.4.4 Total and Average Upfront Values of Top Therapy Areas.....
- 14.4.5 Comparison of Short- and Long-Term Deal Investment .....

# Tables

1.1	Definition of the indications used in the report.....
1.2	Definition of the CorpMETRx metrics used in the report.....
2.1	Top 12 pharmaceutical companies ranked by total number of M&A and Licensing deals over five year and 12 month periods. ....
2.2	Five year and 12 month rankings of M&A activity of the top companies .....
2.3	Five year and 12 month rankings of deal activity of the top companies .....
2.4	Rankings of top companies 12 month licensing deal activity versus five year patent risk.....
2.5	Rankings of top companies 12 month licensing deal activity versus 2011 sales .....

## Company-specific tables:

x.1	M&A activity and ranking vs peer group
x.2	Top M&A deals in the last 5 years by disclosed value
x.3	Overall licensing activity rankings
x.4	Top five therapy areas by percentage revenue in 2011 (Rx and OTC)
x.5	Therapy area activity
x.6	Top oncology deals by disclosed upfront payment
x.7	Short and long-term deal comparison
x.8	Top late stage deals by disclosed upfront payment
x.9	Top early stage deals by disclosed total deal value

# Figures

- 2.1 Total M&A and Licensing deal activities of the top companies .....
- 2.2 M&A and Licensing deal volume over the last 12 months compared with the average 12 month deal volume over the last five years .....
- 2.3 Five year and 12 month M&A activity of the top 12 companies .....
- 2.4 M&A deal volume over the last 12 months compared with the average 12 month deal volume over the last five years.....
- 2.5 Five-year mean M&A total deal values .....
- 2.6 Five-year mean M&A total deal values without the mega mergers.....
- 2.7 Five year and 12 month licensing deal activity of the top companies .....
- 2.8 Licensing deal volume over the last 12 months compared with the average 12 month deal volume over the last five years.....
- 2.9 Five year total licensing deal values for the top 12 companies .....
- 2.10 Five year average total licensing deal values for the top 12 companies .....
- 2.11 Five year total upfront payments for licensing deals of the top 12 companies .....
- 2.12 Five year average upfront payments for licensing deals of the top 12 companies .....
- 2.13 12 Month licensing deal activity versus five year patent risk.....
- 2.14 12 Month licensing deal activity versus 2011 sales (Q2 2011 to Q1 2012) .....
- 2.15 Percentage of deals completed by phase of development over a five year period.....
- 2.16 Percentage of deals completed by phase of development over 12 month period .....
- 2.17 Early stage deals by company .....
- 2.18 Mid-stage deals by company .....
- 2.19 Late stage deals by company .....
- 2.20 Therapy area focus of the top companies .....
- 2.21 Therapy area deal making as a proportion of the total licensing deals.....

## Company-specific figures:

- x.1 2007-2012 Licensing and M&A deal activity
- x.2 Deals vs Peers, deals/2011, deals/5 year patent risk
- x.3 Deal activity in the company's lead therapy area by current sales
- x.4 Therapy focus for dealmaking over the last 5 years
- x.5 Oncology dealmaking against the competition
- x.6 Total deal values of the top 5 therapy areas
- x.7 Average upfront payments for the leading therapy areas